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Pulmonary hypertension (PH) is a complex, heterogeneous disease of great importance to 
the field of kidney transplantation (KT). Patients with end-stage renal disease (ESRD) have 
comorbid cardiovascular and pulmonary disease, and often suffer from volume overload. Not 
surprisingly, they are frequently diagnosed with PH, with an overall reported incidence around 
20-45% in dialysis patients.1 The usual criterion for diagnosing PH is a mean pulmonary artery 
(PA) pressure  25 mmHg, corresponding to a right ventricular systolic pressure (RVSP)  35-40 
mmHg measured by echocardiography. Simply diagnosing elevated PA pressures in patients 
awaiting KT is insufficient; it is also crucial to distinguish the etiology and hemodynamic 
phenotypes of PH (Figure).2 Due to a high incidence of hypertensive heart disease and diastolic 
dysfunction, many ESRD patients have World Health Organization (WHO) Group 2 PH, also 
termed “post-capillary” or PH secondary to left heart disease.3 A minority have WHO Group 1 
PH, also known as “pre-capillary” or pulmonary arterial hypertension (PAH), due to remodeling 
and narrowing of pulmonary arterioles. Finally, PH due to ESRD itself, in absence of other clear 
etiologies, is categorized as WHO Group 5. Proposed mechanisms of Group 5 PH include high 
cardiac output from arteriovenous fistulae, neurohumoral changes of uremia, and 
hyperparathyroidism. In many cases it is challenging or impossible to tease out a single cause of 
PH in an individual ESRD patient. Mixed, overlapping etiologies may exist (Figure). The 
implications of various PH categories for pre- and post-transplant outcomes and prognosis, and 
the optimal treatment strategies for each, are incompletely known. 
The article by Caughey et al. in this issue of Transplantation addresses several of these 
issues.4 The authors utilize the University of North Carolina Cardiorenal Registry, a large (n = 
788 patients) single-center, prospectively-collected cohort of ESRD patients evaluated for KT. 
All patients were screened for PH by transthoracic echocardiography (TTE), performed on an 
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interdialytic day, and read by a single cardiologist. Tricuspid regurgitant jet velocity  2.9 m/s, 
representing an RVSP of approximately 40 mmHg, was considered diagnostic of PH. Doppler 
measurements of left heart diastology were also performed to assess for elevated left atrial 
pressure (eLAP). The implication is that patients with PH and eLAP have a post-capillary (WHO 
Group 2 or 5) contribution to PH – largely expected for a heavily dialyzed population (73% of 
patients in the study). Surprisingly, over half of the patients in Caughey et al. with PH lacked 
Doppler evidence of eLAP – suggesting a pre-capillary etiology. In a survival analysis (median 
follow-up of 4.4 years), the subgroup of PH without eLAP was at highest risk for mortality 
within five years of evaluation for KT, with a hazard ratio (HR) of 2.96 compared to the 
reference group lacking both PH and eLAP. Patients with eLAP, regardless of PH status, had a 
modestly increased risk of death (HR ~1.6).  
The reliance on a single echocardiogram in Caughey et al. to both diagnose and 
categorize PH has several potential problems. First, the gold standard for diagnosis of PH is right 
heart catheterization (RHC), which allows precise measurement of pulmonary hemodynamics. 
The agreement between TTE and RHC for diagnosing PH is imperfect, with a reported 
sensitivity of 83% and specificity of 72%.5 The accuracy of eLAP determination by TTE may be 
particularly problematic considering that intravascular volume depends on timing relative to 
dialysis. PA pressures and pulmonary capillary wedge pressure are reduced after dialysis, and in 
one small study it was only possible to diagnose pre-capillary PH by RHC after dialysis with 
patients close to their dry weight.6 In Caughey et al., all patients underwent TTE on the day 
before dialysis; in this setting, it is surprising that only 45% of patients with PH also had eLAP 
(compared to the 80-100% reported in comparable studies using RHC).6,7 This discrepancy may 
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be due to the relatively strict TTE criteria (Grade 2 diastolic dysfunction) employed by Caughey 
et al. to diagnose eLAP. 
Diagnostic dilemmas aside, how should providers caring for patients awaiting KT utilize 
this information? The poorer outcome in patients with predominantly pre-capillary PH begs the 
question of whether more aggressive identification and management of these can improve 
outcomes. While it is impractical to screen all candidates with RHC, patients with moderate or 
severely elevated RVSP ( 45 mmHg) on TTE, corresponding to about 10-15% of the UNC 
Cardiorenal cohort, are more likely to have PH physiology beyond simple volume overload.3 
Referring such patients for RHC will clarify the etiology as pre-capillary, post-capillary, or 
mixed. For those with predominantly pre-capillary PH, nephrologists should consider 
consultation with a PH specialist for advanced management (Figure). Specialists may initiate and 
titrate modern pulmonary vasodilator therapies such as endothelin receptor antagonists, 
phosphodiesterase type 5 inhibitors, and prostacyclins.3 Whether these will improve wait-list 
survival is unknown - management was not captured in the Caughey et al. study. Optimistically, 
it may be possible to improve post-transplant outcomes with targeted therapy. Several studies 
suggest worse allograft function and survival in PH patients after KT,8,9 possibly due to reduced 
cardiac output and impaired graft perfusion.10 The findings in Caughey et al. present both 
challenges and opportunities: to better characterize and appropriately manage PH in KT 
candidates, define the influence of PH on outcomes, and hopefully one day improve pre- and 
post-transplant survival in this population. 
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Figure legend: 
 
Figure. Diagnosis and categorization of pulmonary hypertension (PH) in patients with end-stage 
renal disease (ESRD) referred for kidney transplant. The blue pathway shows consequences, and 
possible opportunities, for patients with predominantly pre-capillary PH. Abbreviations: HR, 
hazard ratio; LAP, left atrial pressure; PASP, pulmonary artery systolic pressure; PVR, 
pulmonary vascular resistance; TTE, transthoracic echocardiogram; WHO, World Health 
Organization. 
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